Gene Variants Predict Child Neuroblastoma Risk
By LabMedica International staff writers Posted on 02 Oct 2017 |
Image: A photomicrograph of a typical neuroblastoma with rosette formation (Photo courtesy of the U.S. National Cancer Institute).
Potential biomarkers predicting a child's risk for developing neuroblastoma are linked to common variants in the MMP20 (matrix metalloproteinase-20) gene on chromosome 11q.
Investigators at Children's Hospital of Philadelphia (PA, USA) used a genome-wide association study (GWAS) to identify common variants at chromosome locus 11q22.2 within MMP20 that associated with neuroblastoma cases harboring an 11q deletion in 113 European-American cases and 5109 ancestry-matched controls. The association was replicated in 44 independent cases and 1902 controls.
"These inherited variants predispose to 11q deletions, which are a strong risk factor," said Dr. Hakon Hakonarson, director of the center for applied genomics at Children's Hospital of Philadelphia.
"We already knew that 11q deletions are biomarkers that predict poor outcomes in neuroblastoma," said contributing author Dr. John M. Maris, pediatric oncologist at Children's Hospital of Philadelphia. "This new research helps us to more precisely predict how a neuroblastoma tumor will behave, so it improves our diagnostic capabilities."
The study was published in the September 18, 2017, online edition of the journal Nature Communications.
Related Links:
Children's Hospital of Philadelphia
Investigators at Children's Hospital of Philadelphia (PA, USA) used a genome-wide association study (GWAS) to identify common variants at chromosome locus 11q22.2 within MMP20 that associated with neuroblastoma cases harboring an 11q deletion in 113 European-American cases and 5109 ancestry-matched controls. The association was replicated in 44 independent cases and 1902 controls.
"These inherited variants predispose to 11q deletions, which are a strong risk factor," said Dr. Hakon Hakonarson, director of the center for applied genomics at Children's Hospital of Philadelphia.
"We already knew that 11q deletions are biomarkers that predict poor outcomes in neuroblastoma," said contributing author Dr. John M. Maris, pediatric oncologist at Children's Hospital of Philadelphia. "This new research helps us to more precisely predict how a neuroblastoma tumor will behave, so it improves our diagnostic capabilities."
The study was published in the September 18, 2017, online edition of the journal Nature Communications.
Related Links:
Children's Hospital of Philadelphia
Latest Molecular Diagnostics News
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays